Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice
Nicholas B. Hastings, Lili Zhang(San Francisco Foundation), J. Fred Hess, Cathy Ruey-Ruey Huang, Diane E. Grotz, Harold G. Selnick(United States Military Academy), Eric M. Parker(University of New Hampshire), Ganfeng Wang, Giuseppe Terracina, Xiaohai Wang(United States Military Academy), Veeravan Mahadomrongkul, Brent D. Butts, Michaela C. Stanton, Ernest J. McEachern(Alectos (Canada)), David J. Vocadlo(Simon Fraser University), Lixin Song, Julie Lee, Sherry Lu, Xuesong Ouyang(Crown Bioscience (China)), Maureen Laverty, Maureen Maguire, Lynn A. Hyde(Merck & Co., Inc., Rahway, NJ, USA (United States)), Joseph Duffy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Thomas W. Rosahl, Richard Hargreaves(United States Military Academy), Diane Levitan, Kwok-Lam Karen Hong
Cited by 154
Related Papers
Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation
|Journal of Biological Chemistry|2004|716
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
|Science Translational Medicine|2016|416
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition
|Journal of Pharmacology and Experimental Therapeutics|2015|336
Reconstitutively active G protein-coupled receptors purified from baculovirus-infected insect cells.
|Journal of Biological Chemistry|1991|283
O-GlcNAc and neurodegeneration: biochemical mechanisms and potential roles in Alzheimer's disease and beyond
|Chemical Society Reviews|2014|255